VCM
ACAD icon

Voleon Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Voleon Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-46,000
Closed -$1.66M – 173
2019
Q3 		$1.66M Buy
+46,000
New +$1.39M 0.13% 107

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Voleon Capital Management's ACAD Position: Q4 2019 in Review

Voleon Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2019, closing a stake of 46,000 shares — an estimated $1.66M sold.

Voleon Capital Management first reported a position in ACAD in Q3 2019 and held it in 1 quarter. The position peaked at $1.66M in Q3 2019. 273 funds tracked by Wall St. Rank hold ACAD as of Q4 2019.

  • Voleon Capital Management reported no remaining Acadia Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Voleon Capital Management sold 46,000 Acadia Pharmaceuticals shares in Q4 2019, an estimated $1.66M.
  • Voleon Capital Management first reported a position in Acadia Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Voleon Capital Management's Acadia Pharmaceuticals position peaked at $1.66M in Q3 2019.
  • 273 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2019.

Based on Voleon Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.